Sierra Oncology (SRRA) Shares Up 10.5%

Shares of Sierra Oncology Inc (NASDAQ:SRRA) shot up 10.5% during mid-day trading on Tuesday . The company traded as high as $3.75 and last traded at $3.57. 1,262,393 shares changed hands during mid-day trading, an increase of 234% from the average session volume of 378,360 shares. The stock had previously closed at $3.23.

A number of research firms have issued reports on SRRA. Zacks Investment Research cut shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Jefferies Group upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. Finally, ValuEngine upgraded shares of Sierra Oncology from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $4.00.

The firm has a market capitalization of $186.70 and a P/E ratio of -3.76.

Sierra Oncology (NASDAQ:SRRA) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.03. research analysts anticipate that Sierra Oncology Inc will post -0.85 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/12/26/sierra-oncology-srra-shares-up-10-5-2.html.

About Sierra Oncology

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

What are top analysts saying about Sierra Oncology? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sierra Oncology and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit